---
id: nitazoxanide-spectrum_258
category: antimicrobials
tags: [antiprotozoal, nitazoxanide, cryptosporidium, broad-spectrum]
deck: Infectious Diseases
created: 2025-01-11
modified: 2025-01-11
---

## Nitazoxanide: Broad-Spectrum Antiprotozoal

**Q:** How does nitazoxanide differ from metronidazole in mechanism and spectrum? What are its FDA-approved indications?

**A:**

**Mechanism:**
- Nitrothiazole benzamide (NOT a nitroimidazole)
- Inhibits **PFOR-dependent electron transfer** (blocks anaerobic energy metabolism)
- Multiple pathways beyond PFOR (broader than metronidazole)

**Broad Spectrum (vs metronidazole):**
- **Protozoa:** *Giardia*, *Cryptosporidium*, *Entamoeba*, *Cyclospora*
- **Helminths:** *Hymenolepis nana*, *Ascaris lumbricoides*
- **Anaerobic bacteria**
- **Antiviral activity** (inhibits viral replication)

**FDA Indications (immunocompetent patients):**
- *Cryptosporidium parvum* diarrhea (adults + children ≥1 year)
- *Giardia lamblia* (adults + children ≥1 year)

**Key Advantage:** First-line for **cryptosporidiosis** (no alternative for immunocompetent; limited options for HIV)

**Dosing:** 500 mg PO BID × 3 days (adults)

**Media:**

**Sources:** [DrugBank Nitazoxanide], [PMC4920633 - Nitazoxanide Broad Spectrum], [FDA Label 2021], [PMC7113776 - Antiviral Activity]
